Skip to main content
. Author manuscript; available in PMC: 2015 Apr 22.
Published in final edited form as: Nat Med. 2015 Jan 19;21(2):178–184. doi: 10.1038/nm.3788

Figure 2.

Figure 2

(R)-2-HG sensitizes AML cells to pharmacologic BCL-2 inhibition. (a) Viability of the engineered THP-1 cell lines cultured in the absence or presence of doxycycline (dox) and treated with serial dilutions of ABT-199 for 5 days. (b) Viability of parental THP-1 cells treated with serial dilutions of ABT-199 in the presence of 300 μM of octyl-(R)-2-HG or PBS (vehicle control) for two days. (c) Viability of FACS-sorted blasts from the indicated primary AML samples treated with serial dilutions of ABT-199 in the presence of octyl-(R)-2-HG (250 μM for SU353 and 500 μM for SU463) or PBS (vehicle control) for 24 hours. (d) Viability of the engineered mutant IDH1R132H–expressing THP-1 cell line treated with DMSO, ABT-199 (200 nM) and/or the mutant IDH1 inhibitor (mIDH1 inh; AGI-5198 at 10 μM) for five days either in the absence or presence of doxycycline. The data shown in this figure are the means of three biological replicates. *P < 0.05. Statistical significance (P) was determined by Student’s t-test. All error bars represent sd.